CYTOKINE RECEPTOR ZCYTOR17
First Claim
1. An isolated polypeptide comprising an amino acid sequence having at least 95% sequence identity with amino acid residues 33-662 of SEQ ID NO:
- 54, wherein the polypeptide stimulates inflammation upon binding zcytor17 ligand.
0 Assignments
0 Petitions
Accused Products
Abstract
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytorl7, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
-
Citations
13 Claims
-
1. An isolated polypeptide comprising an amino acid sequence having at least 95% sequence identity with amino acid residues 33-662 of SEQ ID NO:
- 54, wherein the polypeptide stimulates inflammation upon binding zcytor17 ligand.
- View Dependent Claims (2, 3)
-
4. An isolated zcytor17 soluble receptor comprising an amino acid sequence having at least 95% sequence identity with amino acid residues 33-532 of SEQ ID NO:
- 54, wherein the zcytor17 soluble receptor reduces zcytor17 ligand induced inflammation.
- View Dependent Claims (5, 6)
- 7. An isolated polypeptide comprising amino acid residues 33-662 of SEQ ID NO:
- 9. An isolated zcytor17 soluble receptor comprising an amino acid sequence of 33-532 of SEQ ID NO:
-
11. A composition comprising:
-
a polypeptide comprising amino acid residues 33-662 of SEQ ID NO;
54; and
a pharmaceutically acceptable vehicle.
-
-
12. A composition comprising:
-
a zcytor17 soluble receptor comprising amino acid residues 33-532 of SEQ ID NO;
54; and
a pharmaceutically acceptable vehicle. - View Dependent Claims (13)
-
Specification